Zobrazeno 1 - 3
of 3
pro vyhledávání: '"621"'
Autor:
Anthony R. Mato, David F. Claxton, Bruce D. Cheson, Jeffrey J. Pu, Clive S. Zent, Molly Fanning, Colleen Timlin, Lauren E. Strelec, Krista Isaack, Allan-Louie Cruz, Paul M. Barr, Nicole Lamanna, David L. Porter, Catherine Daniel, Daniel J. Landsburg, Spencer Henick Bachow, Chaitra S. Ujjani, Pavel Kiselev, Melissa Yacur, Christina Howlett, Allison M. Winter, Danielle M. Brander, Kaitlin Kennard, Chadi Nabhan, Stephen J. Schuster, Brian T. Hill, Alan P Skarbnik, Sunita D. Nasta
Publikováno v:
Blood. 128:3222-3222
Introduction: Ibrutinib (Ibr) is a kinase inhibitor (KI) indicated for treating CLL. Clinical trials that led to its approval showed that its unique side effects differ from traditional chemotherapy toxicities. We previously reported (Mato et al, ASH
Autor:
Naveen Pemmaraju, Kate J. Newberry, Hagop M. Kantarjian, Jorge E. Cortes, Prithviraj Bose, Naval Daver, Lucia Masarova, Srdan Verstovsek
Publikováno v:
Blood. 128:4250-4250
Introduction: The Dynamic International Prognostic Scoring System-Plus (DIPPS-Plus) for primary myelofibrosis (PMF) categorizes cytogenetic abnormalities as "favorable" and "unfavorable." Abnormalities (Abn) -7/7q-; -5/5q-; i(17q), +8; inv(3); 12p-;
Autor:
Valeria Santini, Barry S. Skikne, Paresh Vyas, Stephen Songer, John Morrill, Richard Stone, Mark D. Minden, Teresa Bernal del Castillo, C.L. Beach, Hartmut Döhner, Haifa Kathrin Al-Ali, Hervé Dombret, Jerry Weaver, John F. Seymour
Publikováno v:
Blood. 128:1638-1638
Background: Karyotype is the strongest independent prognostic factor for survival in AML. The randomized phase 3 AZA-AML-001 study of older patients with AML showed AZA prolonged overall survival (OS) compared with CCR (10.4 vs 6.5 months, respective